News | September 17, 2007

Gaps in Treatments, Guidelines for Chronic Heart Failure

September 18, 2007 - Baseline data from the largest study of U.S.-based heart failure (HF) patients in the outpatient setting demonstrate significant gaps and variation in medical care, particularly for women and the elderly, according to findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) study.

The study, sponsored by Medtronic Inc., was presented in a poster session at the Heart Failure Society of America Annual Scientific Meeting.

"This is the first study of its kind to document the extent to which heart failure patients in the outpatient setting are receiving optimal treatment, as defined by the most recent treatment guidelines," said Gregg C. Fonarow, M.D., co-chair of the IMPROVE HF Scientific Steering Committee and Professor of Medicine at the University of California at Los Angeles.

"The IMPROVE HF data represents real-world management of heart failure patients in a variety of outpatient cardiology practices from all regions of the United States. It shows us that there are gaps and significant variation across these practices in the use of evidence-based, guideline-recommended therapies in eligible patients, especially female and elderly patients," added Fonarow.

Key baseline results from IMPROVE HF include:

* Substantial variation exists across outpatient cardiology practices in the type of treatment provided to heart failure patients. Conformity with performance measures (in eligible patients only) for practices (10th-90th percentiles) was:

-ACE inhibitors/ARB (angiotensin II receptor blockers) (67.9-90.4 percent)
-Beta-blockers (72.3-94.4 percent)
-Aldosterone antagonists (7.1-63 percent)
-Cardiac resynchronization therapy (CRT), including both CRT-Defibrillation and CRT-Pacing only devices (0-80 percent)
-Implantable cardioverter defibrillator (ICD) therapy, including both ICD only and CRT-D devices (26.3-76.2 percent)
-Patient education (29.1-88.9 percent)
-Anticoagulation for atrial fibrillation (AF) (44.4-87.5 percent)
-Less than 30 percent (27.5 percent) of patients assessed at baseline were being treated with all therapies for which they were eligible.
-Eligibility for certain treatments is based upon documented medical information such as New York Heart Association (NYHA) functional class; yet, only 31 percent of records documented NYHA class.
-Women were less likely than men to receive an implantable cardioverter defibrillator (ICD) when indicated (43.1 percent vs. 53 percent; p less than 0.001), education about their condition (59.7 percent vs. 61.9 percent; p=0.026), or anticoagulation treatment for atrial fibrillation (64.8 percent vs. 70.6 percent; p=0.004).
-Older patients were less likely than younger patients to receive certain types of guideline-indicated interventions - particularly ICD/CRT-D therapy
-43 percent in patients greater than 76 years
-57.2 percent in patients greater than 64 to less than or equal to 76 years
-52 percent in patients less than or equal to 64 years; p less than 0.001

IMPROVE HF is a large-scale, prospective study involving approximately 40,000 HF patients from approximately 150 cardiology practices in the U.S. The study is designed to:

* characterize the management of chronic systolic heart failure (EF less than or equal to 35 percent) in the outpatient care setting
* assess the effects of practice-specific performance-improvement measures on patient care
* provide insight into the issues that impede implementation of HF treatment guidelines, such as the documentation of NYHA (New York Heart Association) functional class
* identify methods and tools that will improve the quality of HF care in the outpatient setting, such as patient education

The primary objective of the study is to determine if a relative 20 percent or greater improvement in at least two of the following seven performance measures is possible:

1. ACE inhibitors/ARB (angiotensin II receptor blockers)

2. Beta-blockers

3. Aldosterone antagonists

4. Anticoagulation for atrial fibrillation

5. ICD therapy - including both ICD only and CRT-D devices

6. CRT therapy - including both CRT-D and CRT-P only devices

7. Heart failure patient education such as smoking cessation, exercising, diet, and restricting salt intake

For more information: and

Related Content

Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init